OBJECTIVE: To determine whether differences in short-term virologic failure among commonly used antiretroviral therapy (ART) regimens translate to differences in clinical events in antiretroviral-naïve patients initiating ART. DESIGN: Observational cohort study of patients initiating ART between January 2000 and December 2005. SETTING: The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a collaboration of 15 HIV cohort studies from Canada, Europe, and the United States. STUDY PARTICIPANTS: A total of 13 546 antiretroviral-naïve HIV-positive patients initiating ART with efavirenz, nevirapine, lopinavir/ritonavir, nelfinavir, or abacavir as third drugs in combination with a zidovudine and lamivudine nucleoside reverse transcriptase inhibitor backbone. MAIN OUTCOME MEASURES: Short-term (24-week) virologic failure (>500 copies/ml) and clinical events within 2 years of ART initiation (incident AIDS-defining event, death, and a composite measure of these two outcomes). RESULTS: Compared with efavirenz as initial third drug, short-term virologic failure was more common with all other third drugs evaluated; nevirapine (adjusted odds ratio = 1.87, 95% confidence interval (CI) = 1.58-2.22), lopinavir/ritonavir (1.32, 95% CI = 1.12-1.57), nelfinavir (3.20, 95% CI = 2.74-3.74), and abacavir (2.13, 95% CI = 1.82-2.50). However, the rate of clinical events within 2 years of ART initiation appeared higher only with nevirapine (adjusted hazard ratio for composite outcome measure 1.27, 95% CI = 1.04-1.56) and abacavir (1.22, 95% CI = 1.00-1.48). CONCLUSION: Among antiretroviral-naïve patients initiating therapy, between-ART regimen, differences in short-term virologic failure do not necessarily translate to differences in clinical outcomes. Our results should be interpreted with caution because of the possibility of residual confounding by indication.
OBJECTIVE: To determine whether differences in short-term virologic failure among commonly used antiretroviral therapy (ART) regimens translate to differences in clinical events in antiretroviral-naïve patients initiating ART. DESIGN: Observational cohort study of patients initiating ART between January 2000 and December 2005. SETTING: The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a collaboration of 15 HIV cohort studies from Canada, Europe, and the United States. STUDY PARTICIPANTS: A total of 13 546 antiretroviral-naïve HIV-positive patients initiating ART with efavirenz, nevirapine, lopinavir/ritonavir, nelfinavir, or abacavir as third drugs in combination with a zidovudine and lamivudinenucleoside reverse transcriptase inhibitor backbone. MAIN OUTCOME MEASURES: Short-term (24-week) virologic failure (>500 copies/ml) and clinical events within 2 years of ART initiation (incident AIDS-defining event, death, and a composite measure of these two outcomes). RESULTS: Compared with efavirenz as initial third drug, short-term virologic failure was more common with all other third drugs evaluated; nevirapine (adjusted odds ratio = 1.87, 95% confidence interval (CI) = 1.58-2.22), lopinavir/ritonavir (1.32, 95% CI = 1.12-1.57), nelfinavir (3.20, 95% CI = 2.74-3.74), and abacavir (2.13, 95% CI = 1.82-2.50). However, the rate of clinical events within 2 years of ART initiation appeared higher only with nevirapine (adjusted hazard ratio for composite outcome measure 1.27, 95% CI = 1.04-1.56) and abacavir (1.22, 95% CI = 1.00-1.48). CONCLUSION: Among antiretroviral-naïve patients initiating therapy, between-ART regimen, differences in short-term virologic failure do not necessarily translate to differences in clinical outcomes. Our results should be interpreted with caution because of the possibility of residual confounding by indication.
Authors: S A Rhone; R S Hogg; B Yip; C Sherlock; B Conway; M T Schechter; M V O'Shaughnessy; J S Montaner Journal: AIDS Date: 1998-04-16 Impact factor: 4.177
Authors: S Grabar; V Le Moing; C Goujard; C Leport; M D Kazatchkine; D Costagliola; L Weiss Journal: Ann Intern Med Date: 2000-09-19 Impact factor: 25.391
Authors: A C Friedl; B Ledergerber; M Flepp; B Hirschel; A Telenti; H Furrer; H C Bucher; E Bernasconi; R Weber Journal: AIDS Date: 2001-09-28 Impact factor: 4.177
Authors: S L Becker; S R Raffanti; N I Hansen; J S Fusco; G P Fusco; G H Slatko; E F Igboko; N M Graham Journal: J Acquir Immune Defic Syndr Date: 2001-01-01 Impact factor: 3.731
Authors: Benjamin H Chi; Albert Mwango; Mark Giganti; Lloyd B Mulenga; Bushimbwa Tambatamba-Chapula; Stewart E Reid; Carolyn Bolton-Moore; Namwinga Chintu; Priscilla L Mulenga; Elizabeth M Stringer; Robert Sheneberger; Peter Mwaba; Jeffrey S A Stringer Journal: J Acquir Immune Defic Syndr Date: 2010-05-01 Impact factor: 3.731
Authors: Elizabeth L Yanik; Sonia Napravnik; Patrick Ryscavage; Joseph J Eron; Susan L Koletar; Richard D Moore; Anne Zinski; Stephen R Cole; Peter Hunt; Heidi M Crane; James Kahn; William C Mathews; Kenneth H Mayer; Babafemi O Taiwo Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Margaret T May; Suzanne M Ingle; Dominique Costagliola; Amy C Justice; Frank de Wolf; Matthias Cavassini; Antonella D'Arminio Monforte; Jordi Casabona; Robert S Hogg; Amanda Mocroft; Fiona C Lampe; François Dabis; Gerd Fätkenheuer; Timothy R Sterling; Julia del Amo; M John Gill; Heidi M Crane; Michael S Saag; Jodie Guest; Hans-Reinhard Brodt; Jonathan A C Sterne Journal: Int J Epidemiol Date: 2013-04-18 Impact factor: 7.196